Sack­lers threat­en to walk away from Pur­due opi­oid set­tle­ment as anger builds over im­mu­ni­ty pro­vi­sions — re­port

4 years ago
Pharma

Stu­art Schreiber’s bid to tack­le huge class of cru­cial pro­teins nabs an­oth­er $50M

4 years ago
Financing

Vig­il rais­es $90M in neu­ro­science 're­nais­sance.' Is an IPO around the cor­ner?

4 years ago
Financing

Ver­i­ly scoops up a fel­low soft­ware mak­er as Amy Aber­nethy scales its clin­i­cal tri­als plat­form

4 years ago
Deals
Outsourcing

Still reel­ing from Ze­ju­la set­back, Glax­o­SmithK­line gets a breather with ex­pand­ed PD-1 ap­proval

4 years ago
Pharma
FDA+

Tout­ing CD161 as a test case for sin­gle-cell tech, Long­wood-backed Im­mu­ni­tas bags $58M for next-gen I/O work

4 years ago
Financing

Ex­e­Vir dos­es first pa­tients with lla­ma-de­rived an­ti-Covid an­ti­body

4 years ago
Coronavirus

Search­ing for ways to boost CAR-T re­sponse, Penn re­searchers find a ca­pa­ble wing­man in BET in­hibitors

4 years ago
Discovery
Cell/Gene Tx

SEC charges for­mer Medi­va­tion ex­ec with in­sid­er trad­ing pri­or to Pfiz­er ac­qui­si­tion

4 years ago
People
Pharma

Au­rinia gets two new as­sets in ac­qui­si­tion, li­cens­ing deal; Shorla preps T-cell leukemia drug for com­mer­cial­iza­tion

4 years ago
News Briefing

Through a man­u­fac­tur­ing deal, Africa was sup­posed to fi­nal­ly get up to speed on Covid-19 vac­cines. Now, those have ...

4 years ago
Coronavirus
Manufacturing

Next-gen pso­ri­a­sis drug ri­val­ry be­tween Bris­tol My­ers and Nim­bus spills in­to a le­gal bat­tle

4 years ago
R&D
Pharma

Eli Lil­ly un­veils a com­plete makeover, erect­ing a neu­ro­science unit cen­tered on Alzheimer's as it uni­fies on­col­o­gy ...

4 years ago
Pharma

Du­el­ing 7-fig­ure ad cam­paigns set sights on a big drug price ne­go­ti­a­tion bill com­ing soon

4 years ago
Pharma

End­points News wants to know: Is your com­pa­ny man­dat­ing Covid-19 vac­cines?

4 years ago
Editor's note
Pharma

Covid-19 roundup: CEPI in­jects $20.6M in­to Grit­stone's push for a next-gen vac­cine; Quali­gen shelves its Covid-19 ...

4 years ago
Coronavirus

In­no­Care bags Chi­nese rights to In­cyte CAR-T ri­val Mon­ju­vi in bid to ex­pand in-house pipeline

4 years ago
Deals
China

Mag­ic mush­rooms and 'toad ven­om' get this British biotech an over­sub­scribed Se­ries B

4 years ago
Financing

Scoop: Adam Kop­pel's Bain team has an­oth­er $1.9B to wa­ger on life sci com­pa­nies. And he likes their odds

4 years ago
Bioregnum

Af­ter the long, gru­el­ing path to EUA, Roche says there is a sup­ply short­age of Actem­ra

4 years ago
Pharma
Coronavirus

Can­cer spe­cial­ist Hi­ber­Cell snaps up an­a­lyt­ics, com­pu­ta­tion­al tools in all-stock buy­out; Prax­is re­veals new ...

4 years ago
News Briefing

Sev­er­al months af­ter re­brand­ing, an old Mar­tin Shkre­li com­pa­ny touts promis­ing piv­otal da­ta in a rare kid­ney dis­or­der

4 years ago
R&D

As Biden sig­nals in­ter­est in link­ing drug prices with R&D costs, new study finds costs per NME are in­creas­ing

4 years ago
R&D

Boehringer In­gel­heim scraps $600M+ lung can­cer pro­gram with Cure­Vac, as the biotech preps its sec­ond Covid-19 shot

4 years ago
Deals
R&D
First page Previous page 650651652653654655656 Next page Last page
A service from the Financial Times